M. M-Garcia
10/635808

=> dis his

(FILE 'CAOLD' ENTERED AT 10:16:32 ON 28 SEP 2004)
DEL HIS Y

FILE 'REGISTRY' ENTERED AT 10:16:44 ON 28 SEP 2004
L1 STR
L2 50 S L1
L3 STR L1
L4 1 S L3
L5 STR L3
L6 308 S L5 FUL

=> d l6 que stat;fil medl,hcapl,embase,biosis;s l6
L5 STR

Ak NH @17 18 | O Ak @19 20 | Ak N Ak 21 @22 23 | C=O @31 32 | CH2 C=O @33 @34 35



CH2 CH2 C=O @36 37 @38 39

CH2 CH2 CH2 C=O @40 41 42 @43 44 | CH=CH C=O @45 46 @47 48 | O~CH2 C=O @49 50 @51 52

VAR G1=OH/19/NH2/17/22
VAR G2=31/33-25 34-11/36-25 38-11/40-25 43-11/45-25 47-11/49-25 51-11
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 52

STEREO ATTRIBUTES: NONE
L6 308 SEA FILE=REGISTRY SSS FUL L5

100.0% PROCESSED 294255 ITERATIONS 308 ANSWERS
SEARCH TIME: 00.00.27

COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.34	690.09

Searched by: Mary Hale 571-272-2507 REM 1D86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION

CA SUBSCRIBER PRICE 0.00 -37.10

FILE 'MEDLINE' ENTERED AT 10:33:09 ON 28 SEP 2004

FILE 'HCAPLUS' ENTERED AT 10:33:09 ON 28 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'EMBASE' ENTERED AT 10:33:09 ON 28 SEP 2004

FILE 'BIOSIS' ENTERED AT 10:33:09 ON 28 SEP 2004

L7 44 FILE MEDLINE
L8 174 FILE HCAPLUS
L9 16 FILE EMBASE
L10 0 FILE BIOSIS

TOTAL FOR ALL FILES
L11 234 L6

=> s l11 and (postlesion? or post lesion? or neurodegenerat? or neurolog? degen? or alzheimer? or dement? or cognitive impairment or neural trauma)
L12 0 FILE MEDLINE
L13 3 FILE HCAPLUS
L14 0 FILE EMBASE
L15 0 FILE BIOSIS

TOTAL FOR ALL FILES
L16 3 L11 AND (POSTLESION? OR POST LESION? OR NEURODEGENERAT? OR NEURO LOG? DEGEN? OR ALZHEIMER? OR DEMENT? OR COGNITIVE IMPAIRMENT OR NEURAL TRAUMA)

=> d 1-3 cbib abs hitstr

L16 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN
2002:609522 Document No. 137:163818 Tripeptide derivatives for the treatment of **post-lesional** diseases of the nervous system.
Rapin, Jean; Witzmann, Hans Klaus; Grumel, Jean-Marie; Gonella, Jacques (Tell-Pharm AG, Switz.). Ger. Offen. DE 10105040 A1 20020814, 4 pp. (German). CODEN: GWXXBX. APPLICATION: DE 2001-10105040 20010205.
GI



AB The invention discloses the use of cinnamoyl tripeptide derivs. for the

Searched by: Mary Hale 571-272-2507 REM 1D86

treatment of **post-lesional** neuronal diseases. The cinnamoyl tripeptide derivs. are I [X = OH, C1-5 alkoxy, NH2, NH(C1-5 alkyl), N(C1-5 alkyl)2; R = (preferably) cinnamoyl; R1 = group derived from Phe, Tyr, Trp, Pro, Ala, Val, Leu or Ile; R2 = group derived from Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp and Asn; R3, R4 = H, OH, C1-5 alkyl, C1-5 alkoxy, provided that R3 and R4 are not both OH or C1-5 alkoxy; R5 = H, OH, C1-5 alkyl, C1-5 alkoxy], or a pharmaceutical acceptable salt thereof.

IT **123910-57-6**
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tripeptide derivs. for treatment of **post-lesional** nervous system diseases)

RN 123910-57-6 HCAPLUS

CN L-Prolinamide, N-(1-oxo-3-phenyl-2-propenyl)glycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L16 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN

2002:591566 Document No. 137:135103 Tripeptide derivatives for treatment of **neurodegenerative** diseases. Rapin, Jean; Witzmann, Hans Klaus; Grumel, Jean-Marie; Gonella, Jacques (Tell-Pharm A.-G., Switz.). Ger. Offen. DE 10105039 A1 20020808, 10 pp. (German). CODEN: GWXXBX. APPLICATION: DE 2001-10105039 20010205.

GI



AB The invention discloses the use of tripeptide derivs. for treatment of **neurodegenerative** diseases. The tripeptide derivs. are I [X = OH, C1-5 alkoxy, NH2, NH(C1-5 alkyl), N(C1-5 alkyl)2; R = (preferably) cinnamoyl; R1 = group derived from Phe, Tyr, Trp, Pro, Ala, Val, Leu or Ile; R2 = group derived from Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys,

Pro, Glu, Gln, pGlu, Asp or Asn; R3, R4 = H, OH, C1-5 alkyl, C1-5 alkoxy, provided that R3 and R4 are not both OH or C1-5 alkoxy; R5 = H, OH, C1-5 alkyl, C1-5 alkoxy], or a pharmaceutically compatible salt. Cinnamoyl-Gly-L-Phe-L-Pro-NH2 was tested in an **Alzheimer**'s disease model.

IT **123910-57-6**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tripeptide derivs. for treatment of **neurodegenerative** diseases)

RN 123910-57-6 HCAPLUS

CN L-Prolinamide, N-(1-oxo-3-phenyl-2-propenyl)glycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L16 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN

1989:633680 Document No. 111:233680 Preparation of tripeptides containing L-proline derivatives as nootropics and pharmaceutical compositions containing them. Fiez-Vandal, Pierre Yves (Inorgan S. A., Switz.). Eur. Pat. Appl. EP 316218 A1 19890517, 18 pp. DESIGNATED STATES: R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE. (French). CODEN: EPXXDW. APPLICATION: EP 1988-402761 19881103. PRIORITY: FR 1987-15228 19871103.

GI

AB The title compds. [I; R1 = Q; X = CO, YCO, OYCO; Y = alkylene, alkenylene; Z = H, ≥1 CF3, alkyl, alkylenedioxy; R2 = NH2, OH, or a functional derivative thereof; A1, A2 = amino acid residue; B1, B2 = H, Me] and their pharmaceutically acceptable salts, useful as nootropics for treatment of senile **dementia**, **Alzheimer**'s disease, Parkinson's disease, schizophrenia, and depression, are prepared via reaction of activated R1-A1-OH with proline derivs. II (R3 = H-A2), obtained by reaction of II (R3 = H) with activated H-A2-OH. N-Cinnamoylglycine (preparation given) was condensed with II.CF3CO2H (R2 = NH2, B1 = B2 = H, R3 = H-Phe)(preparation given) in DMF containing dicyclohexylcarbodiimide and N-methylmorpholine to give I (R1 = cinnamoyl, R2 = NH2, B1 = B2 = H, A1 =

Gly, A2 = Phe) (III). III, administered i.p. or p.o. at 1 mg/kg, was effective in antagonizing scopolamine-induced amnesia in mice.

IT **123910-50-9P 123910-52-1P 123910-53-2P**
123910-54-3P 123910-55-4P 123910-56-5P
123910-57-6P 123910-58-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as nootropic)

RN 123910-50-9 HCAPLUS
CN L-Prolinamide, N-[3-(4-fluorophenyl)-1-oxo-2-propenyl]glycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 123910-52-1 HCAPLUS
CN L-Prolinamide, N-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]glycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 123910-53-2 HCAPLUS
CN L-Prolinamide, N-(1-oxo-3-phenyl-2-propenyl)glycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 123910-54-3 HCAPLUS
CN L-Prolinamide, N-benzoylglycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123910-55-4 HCAPLUS
CN L-Prolinamide, N-(phenylacetyl)glycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123910-56-5 HCAPLUS
CN L-Proline, 4,4-dimethyl-1-[N-[N-(1-oxo-3-phenyl-2-propenyl)glycyl]-L-phenylalanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

Searched by: Mary Hale 571-272-2507 REM 1D86



RN 123910-57-6 HCAPLUS
CN L-Prolinamide, N-(1-oxo-3-phenyl-2-propenyl)glycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 123910-58-7 HCAPLUS
CN L-Prolinamide, N-[3-(1,3-benzodioxol-5-yl)-1-oxo-2-propenyl]glycyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



=> fil hcapl;e postlesional/ct

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	38.79	728.88

Searched by: Mary Hale 571-272-2507 REM 1D86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION

CA SUBSCRIBER PRICE -2.10 -39.20

FILE 'HCAPLUS' ENTERED AT 10:36:25 ON 28 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 Sep 2004 VOL 141 ISS 14
FILE LAST UPDATED: 27 Sep 2004 (20040927/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

E#	FREQUENCY	AT		TERM
E1	0	1		POSTIMPLANTATION/CT
E2	0	2		POSTIMPLANTATION EMBRYO/CT
E3	0		-->	POSTLESIONAL/CT
E4	0	1		POSTMENOPAUSAL/CT
E5	0	2		POSTMENOPAUSAL BONE LOSS/CT
E6	0	2		POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY/CT
E7	0	2		POSTMENOPAUSAL OSTEOPOROSIS/CT
E8	0	2		POSTMENOPAUSE/CT
E9	0	1		POSTMORTEM/CT
E10	0	2		POSTMORTEM HUMAN TISSUE/CT
E11	0	1		POSTNATAL/CT
E12	0	2		POSTNATAL DEPRESSION/CT

=> e neurodegenerative/ct

E#	FREQUENCY	AT		TERM
E1	0	1		NEUROD3/CT
E2	0	2		NEURODEGENERATION/CT
E3	0	1	-->	NEURODEGENERATIVE/CT
E4	0	2		NEURODEGENERATIVE DISEASE/CT
E5	0	2		NEURODEGENERATIVE DISEASES/CT
E6	0	2		NEURODEGENERATIVE DISORDER/CT
E7	0	2		NEURODEGENERATIVE DISORDERS/CT
E8	0	2		NEURODERMATITIS/CT
E9	1			NEURODIA CYCLOPION FLORIDANA/CT
E10	0	2		NEUROECTODERM/CT
E11	0	2		NEUROECTODERM NEOPLASM/CT
E12	0	2		NEUROECTODERM TUMORS/CT

=> e e3+all

E1	0	-->	Neurodegenerative/CT

********** END **********

Searched by: Mary Hale 571-272-2507 REM 1D86

```
=> e alzheimer?/ct
E#   FREQUENCY     AT      TERM
--   ---------     --      ----
E1           0      1      ALZHEIMER-TYPE/CT
E2           0      2      ALZHEIMER-TYPE SENILE DEMENTIA/CT
E3           0        --> ALZHEIMER?/CT
E4           0      1      AM/CT
E5           0      2      AM 0.5/CT
E6           0      2      AM 1002/CT
E7           0      2      AM 100L/CT
E8           0      2      AM 111/CT
E9           0      2      AM 2000UP/CT
E10          0      2      AM 6/CT
E11          0      2      AM BLACK/CT
E12          0      2      AM MICROBIAL GENE AND GENETIC ELEMENT/CT

=> e alzheimers/ct
E#   FREQUENCY     AT      TERM
--   ---------     --      ----
E1           0      1      ALZHEIMER-TYPE/CT
E2           0      2      ALZHEIMER-TYPE SENILE DEMENTIA/CT
E3           0        --> ALZHEIMERS/CT
E4           0      1      AM/CT
E5           0      2      AM 0.5/CT
E6           0      2      AM 1002/CT
E7           0      2      AM 100L/CT
E8           0      2      AM 111/CT
E9           0      2      AM 2000UP/CT
E10          0      2      AM 6/CT
E11          0      2      AM BLACK/CT
E12          0      2      AM MICROBIAL GENE AND GENETIC ELEMENT/CT

=> e cognitive impairment/ct
E#   FREQUENCY     AT      TERM
--   ---------     --      ----
E1           0      2      COGNITIVE BEHAVIOR/CT
E2           0      3      COGNITIVE DISORDERS/CT
E3           0      3 --> COGNITIVE IMPAIRMENT/CT
E4           0      3      COGNITIVE MENTAL DISORDER/CT
E5           0      1      COGON/CT
E6           0      2      COGON GRASS/CT
E7           2             COGWHEELS/CT
E8           0      1      COH/CT
E9           0      1      COHAERENS/CT
E10          0      1      COHEN/CT
E11          2      2      COHEN SYNDROME/CT
E12          9             COHEN, ERNST/CT

=> e e3+all
E1           0   -->  Cognitive impairment/CT
E2                 USE  Cognition (L) disorder/CT
E3                 USE  Mental disorder (L) cognitive/CT
********** END **********

=> e neural trauma/ct
E#   FREQUENCY     AT      TERM
--   ---------     --      ----
E1           0      2      NEURAL TISSUE-SPECIFIC F-ACTIN-BINDING PROTEINS/CT
E2           0      3      NEURAL TRANSPLANT/CT
E3           0        --> NEURAL TRAUMA/CT
E4           0      2      NEURAL TUBE/CT
```

Searched by: Mary Hale 571-272-2507 REM 1D86

```
E5            0      2     NEURAL TUBE DEFECT/CT
E6            0      2     NEURAL TUBE DEFECTS/CT
E7            0      2     NEURAL TUBE DISEASE/CT
E8            0      2     NEURAL TUBE NERVOUS SYSTEM/CT
E9            0      2     NEURAL TUMORS/CT
E10           0      1     NEURAL-/CT
E11           0      2     NEURAL- AND THYMUS-DERIVED ACTIVATOR FOR ERBB KINASES/
                           CT
E12          55      2     NEURALGIA/CT

=> fil medl,hcapl,embase,biosis;s l11 and (mental disorder(l)cognitive or
cognition(l)disorder)
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       7.08     735.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -39.20

FILE 'MEDLINE' ENTERED AT 10:38:28 ON 28 SEP 2004

FILE 'HCAPLUS' ENTERED AT 10:38:28 ON 28 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:38:28 ON 28 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'BIOSIS' ENTERED AT 10:38:28 ON 28 SEP 2004
Copyright (c) 2004 The Thomson Corporation.


L17           0 FILE MEDLINE
L18           0 FILE HCAPLUS
L19           0 FILE EMBASE
L20           0 FILE BIOSIS

TOTAL FOR ALL FILES
L21           0 L11 AND (MENTAL DISORDER(L) COGNITIVE OR COGNITION(L) DISORDER)

=> s rapin, j?/au;s witzmann, h?/au;s grumel, j?/au;s gonella, j?/au
L22         114 FILE MEDLINE
L23         166 FILE HCAPLUS
L24         131 FILE EMBASE
L25         149 FILE BIOSIS

TOTAL FOR ALL FILES
L26         560 RAPIN, J?/AU


L27           3 FILE MEDLINE
L28         134 FILE HCAPLUS
L29           3 FILE EMBASE
L30           3 FILE BIOSIS

TOTAL FOR ALL FILES
L31         143 WITZMANN, H?/AU


L32           0 FILE MEDLINE

Searched by: Mary Hale 571-272-2507 REM 1D86
```

L33 4 FILE HCAPLUS
L34 2 FILE EMBASE
L35 1 FILE BIOSIS

TOTAL FOR ALL FILES
L36 7 GRUMEL, J?/AU

L37 45 FILE MEDLINE
L38 38 FILE HCAPLUS
L39 29 FILE EMBASE
L40 47 FILE BIOSIS

TOTAL FOR ALL FILES
L41 159 GONELLA, J?/AU

=> s l26 and l31 and l36 and l41
L42 0 FILE MEDLINE
L43 4 FILE HCAPLUS
L44 0 FILE EMBASE
L45 0 FILE BIOSIS

TOTAL FOR ALL FILES
L46 4 L26 AND L31 AND L36 AND L41

=> d 1-4 cbib abs;fil reg

L46 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
2002:609523 Document No. 137:155181 Synthesis of tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases. **Rapin, Jean; Witzmann, Hans Klaus; Grumel, Jean-Marie; Gonella, Jacques** (Tell-Pharm Ag, Switz.). Ger. Offen. DE 10105041 A1 20020814, 12 pp. (German). CODEN: GWXXBX. APPLICATION: DE 2001-10105041 20010205.

AB The invention concerns the use of tripeptide derivs. [e.g., H-Gly-Phe-Pro-NH2 (I)] for the treatment of neurodegenerative disease, such as Alzheimer's disease. Thus, Boc-Phe-OH [Boc = (CH3)3OC(O)] was coupled with TFA.H-Pro-NH2 to give a dipeptide, which was N-deprotected and converted to its TFA salt for coupling with Boc-Gly-OH; the resulting protected tripeptide was N-deprotected and converted to its HCl salt. The blood-brain partition coeffs. of I and seventeen similar tripeptides were given. The plasma half-life of 14C-labeled I.HCl was determined in rats (no data). Using a rat model of Alzheimer's disease, results of treatment with I showed retention of learned behavior in a five-day test of pole-climbing at a signal to avoid shock. Examination of subject brains revealed increase dendrite development in the hippocampus.

L46 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
2002:609522 Document No. 137:163818 Tripeptide derivatives for the treatment of post-lesional diseases of the nervous system. **Rapin, Jean; Witzmann, Hans Klaus; Grumel, Jean-Marie; Gonella, Jacques** (Tell-Pharm AG, Switz.). Ger. Offen. DE 10105040 A1 20020814, 4 pp. (German). CODEN: GWXXBX. APPLICATION: DE 2001-10105040 20010205.

GI

Searched by: Mary Hale 571-272-2507 REM 1D86



I

AB The invention discloses the use of cinnamoyl tripeptide derivs. for the treatment of post-lesional neuronal diseases. The cinnamoyl tripeptide derivs. are I [X = OH, C1-5 alkoxy, NH2, NH(C1-5 alkyl), N(C1-5 alkyl)2; R = (preferably) cinnamoyl; R1 = group derived from Phe, Tyr, Trp, Pro, Ala, Val, Leu or Ile; R2 = group derived from Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp and Asn; R3, R4 = H, OH, C1-5 alkyl, C1-5 alkoxy, provided that R3 and R4 are not both OH or C1-5 alkoxy; R5 = H, OH, C1-5 alkyl, C1-5 alkoxy], or a pharmaceutical acceptable salt thereof.

L46 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
2002:609521 Document No. 137:140781 Synthesis of tripeptides and tripeptide derivatives for the treatment of post lesional diseases of the nervous system.. **Rapin, Jean; Witzmann, Hans Klaus; Grumel, Jean-Marie; Gonella, Jacques** (Tell-Pharm Ag, Switz.). Ger. Offen. DE 10105038 A1 20020814, 10 pp. (German). CODEN: GWXXBX. APPLICATION: DE 2001-10105038 20010205.

AB The invention concerns the use of tripeptide derivs. [e.g., H-Gly-Phe-Pro-NH2 (I)] for the treatment of post lesional diseases of the nervous system. Thus, Boc-Phe-OH [Boc = (CH3)3OC(O)] was coupled with TFA.H-Pro-NH2 to give a dipeptide, which was N-deprotected and converted to its TFA salt for coupling with Boc-Gly-OH; the resulting protected tripeptide was N-deprotected and converted to its HCl salt. The blood-brain partition coeffs. of I and seventeen similar tripeptides were given. The plasma half-life of 14C-labeled I.HCl was determined in rats (no data). Using an in-vivo dendritic sprouting assay in rats, I was tested for effect on hippocampus septum, and showed growth of up to 2μm, compared to controls.

L46 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
2002:591566 Document No. 137:135103 Tripeptide derivatives for treatment of neurodegenerative diseases. **Rapin, Jean; Witzmann, Hans Klaus; Grumel, Jean-Marie; Gonella, Jacques** (Tell-Pharm A.-G., Switz.). Ger. Offen. DE 10105039 A1 20020808, 10 pp. (German). CODEN: GWXXBX. APPLICATION: DE 2001-10105039 20010205.

GI



I

Searched by: Mary Hale 571-272-2507 REM 1D86

AB The invention discloses the use of tripeptide derivs. for treatment of neurodegenerative diseases. The tripeptide derivs. are I [X = OH, C1-5 alkoxy, NH2, NH(C1-5 alkyl), N(C1-5 alkyl)2; R = (preferably) cinnamoyl; R1 = group derived from Phe, Tyr, Trp, Pro, Ala, Val, Leu or Ile; R2 = group derived from Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp or Asn; R3, R4 = H, OH, C1-5 alkyl, C1-5 alkoxy, provided that R3 and R4 are not both OH or C1-5 alkoxy; R5 = H, OH, C1-5 alkyl, C1-5 alkoxy], or a pharmaceutically compatible salt. Cinnamoyl-Gly-L-Phe-L-Pro-NH2 was tested in an Alzheimer's disease model.

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.01	750.97

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.80	-42.00

FILE 'REGISTRY' ENTERED AT 10:40:05 ON 28 SEP 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 SEP 2004 HIGHEST RN 752974-11-1
DICTIONARY FILE UPDATES: 27 SEP 2004 HIGHEST RN 752974-11-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

```
=> e "cinnamoyl-glycyl-l-phenylalanyl-l-prolinamide"/cn
E1            1      CINNAMOYL-COA:(R)-PHENYLLACTATE COA-TRANSFERASE/CN
E2            1      CINNAMOYL-COENZYME A REDUCTASE/CN
E3            0 --> CINNAMOYL-GLYCYL-L-PHENYLALANYL-L-PROLINAMIDE/CN
E4            1      CINNAMOYLACETALDEHYDE/CN
E5            1      CINNAMOYLACETONE/CN
E6            1      CINNAMOYLACETONITRILE/CN
E7            1      CINNAMOYLAUBUCIN/CN
E8            1      CINNAMOYLAUCUBIN/CN
E9            1      CINNAMOYLCHOLINE/CN
E10           1      CINNAMOYLCHOLINE CHLORIDE/CN
E11           1      CINNAMOYLCOCAINE/CN
E12           1      CINNAMOYLDIAMINOPIPERAZINE/CN

=>
=> e
E13           1      CINNAMOYLECGONINE/CN
E14           1      CINNAMOYLECGONINE METHYL ESTER/CN
```

Searched by: Mary Hale 571-272-2507 REM 1D86

```
E15          1      CINNAMOYLETHYL METHACRYLATE-DIMETHYLOCTYLAMMONIUM STYRENESUL
                    FONATE-METHACRYLIC ACID-TRIS(TRIMETHYLSILOXY)(3-(METHACRYLOY
                    LOXY)PROPYL)SILANE COPOLYMER/CN
E16          1      CINNAMOYLETHYL METHACRYLATE-STYRENE BLOCK COPOLYMER/CN
E17          1      CINNAMOYLFERROCENE/CN
E18          1      CINNAMOYLGLUCOSE-ALCOHOL CINNAMOYLTRANSFERASE/CN
E19          1      CINNAMOYLGLYCINE/CN
E20          1      CINNAMOYLGLYCINE P-NITROPHENYL ESTER/CN
E21          1      CINNAMOYLGRANDIFLORIC ACID/CN
E22          1      CINNAMOYLHYDRAZINE/CN
E23          1      CINNAMOYLHYDROXAMIC ACID/CN
E24          1      CINNAMOYLIUM/CN

=> s cinnamoyl(l)glycyl(l)phenylalanyl(l)prolinamide
          3686 CINNAMOYL
             1 CINNAMOYLS
          3686 CINNAMOYL
                 (CINNAMOYL OR CINNAMOYLS)
        492293 GLYCYL
             2 GLYCYLS
        492293 GLYCYL
                 (GLYCYL OR GLYCYLS)
        367484 PHENYLALANYL
         21527 PROLINAMIDE
L47          0 CINNAMOYL(L)GLYCYL(L)PHENYLALANYL(L)PROLINAMIDE

=> e "cinnamoyl-isoleucyl-phenylalanyl-l-proline ethylamide"/cn
E1           1      CINNAMOYL-COA:(R)-PHENYLLACTATE COA-TRANSFERASE/CN
E2           1      CINNAMOYL-COENZYME A REDUCTASE/CN
E3           0 --> CINNAMOYL-ISOLEUCYL-PHENYLALANYL-L-PROLINE ETHYLAMIDE/CN
E4           1      CINNAMOYLACETALDEHYDE/CN
E5           1      CINNAMOYLACETONE/CN
E6           1      CINNAMOYLACETONITRILE/CN
E7           1      CINNAMOYLAUBUCIN/CN
E8           1      CINNAMOYLAUCUBIN/CN
E9           1      CINNAMOYLCHOLINE/CN
E10          1      CINNAMOYLCHOLINE CHLORIDE/CN
E11          1      CINNAMOYLCOCAINE/CN
E12          1      CINNAMOYLDIAMINOPIPERAZINE/CN

=> s cinnamoyl(l)isoleucyl(l)phenylalanyl(l)proline(l)ethylamide
          3686 CINNAMOYL
             1 CINNAMOYLS
          3686 CINNAMOYL
                 (CINNAMOYL OR CINNAMOYLS)
        325112 ISOLEUCYL
        367484 PHENYLALANYL
         85965 PROLINE
             2 PROLINES
         85965 PROLINE
                 (PROLINE OR PROLINES)
           621 ETHYLAMIDE
L48          0 CINNAMOYL(L)ISOLEUCYL(L)PHENYLALANYL(L)PROLINE(L)ETHYLAMIDE

=> e "cinnamoyl-isoleucyl-isoleucyl-prolineamide"/cn
E1           1      CINNAMOYL-COA:(R)-PHENYLLACTATE COA-TRANSFERASE/CN
E2           1      CINNAMOYL-COENZYME A REDUCTASE/CN
E3           0 --> CINNAMOYL-ISOLEUCYL-ISOLEUCYL-PROLINEAMIDE/CN
E4           1      CINNAMOYLACETALDEHYDE/CN
E5           1      CINNAMOYLACETONE/CN
E6           1      CINNAMOYLACETONITRILE/CN
E7           1      CINNAMOYLAUBUCIN/CN
```

Searched by: Mary Hale 571-272-2507 REM 1D86

```
E8            1     CINNAMOYLAUCUBIN/CN
E9            1     CINNAMOYLCHOLINE/CN
E10           1     CINNAMOYLCHOLINE CHLORIDE/CN
E11           1     CINNAMOYLCOCAINE/CN
E12           1     CINNAMOYLDIAMINOPIPERAZINE/CN

=> s cinnamoyl(l)isoleucyl(l)isoleucyl(l)prolineamide
          3686 CINNAMOYL
             1 CINNAMOYLS
          3686 CINNAMOYL
                 (CINNAMOYL OR CINNAMOYLS)
        325112 ISOLEUCYL
        325112 ISOLEUCYL
             2 PROLINEAMIDE
L49          0 CINNAMOYL(L)ISOLEUCYL(L)ISOLEUCYL(L)PROLINEAMIDE

=> fil medl,hcap,biosis,embase,wpids
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      59.69     810.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -42.00

FILE 'MEDLINE' ENTERED AT 10:43:03 ON 28 SEP 2004

FILE 'HCAPLUS' ENTERED AT 10:43:03 ON 28 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:43:03 ON 28 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'EMBASE' ENTERED AT 10:43:03 ON 28 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 10:43:03 ON 28 SEP 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

=> s cinnamoyl(l)isoleucyl(l)isoleucyl(l)prolineamide
L50          0 FILE MEDLINE
L51          0 FILE HCAPLUS
L52          0 FILE BIOSIS
L53          0 FILE EMBASE
L54          0 FILE WPIDS

TOTAL FOR ALL FILES
L55          0 CINNAMOYL(L) ISOLEUCYL(L) ISOLEUCYL(L) PROLINEAMIDE

=> s cinnamoyl(l)isoleucyl(l)phenylalanyl(l)proline(l)ethylamide
L56          0 FILE MEDLINE
L57          0 FILE HCAPLUS
L58          0 FILE BIOSIS
L59          0 FILE EMBASE
L60          0 FILE WPIDS

TOTAL FOR ALL FILES
L61          0 CINNAMOYL(L) ISOLEUCYL(L) PHENYLALANYL(L) PROLINE(L) ETHYLAMIDE

=> s cinnamoyl(l)glycyl(l)phenylalanyl(l)prolinamide

Searched by: Mary Hale 571-272-2507 REM 1D86
```

```
L62             0 FILE MEDLINE
L63             0 FILE HCAPLUS
L64             0 FILE BIOSIS
L65             0 FILE EMBASE
L66             1 FILE WPIDS

TOTAL FOR ALL FILES
L67             1 CINNAMOYL(L) GLYCYL(L) PHENYLALANYL(L) PROLINAMIDE

=> d

L67  ANSWER 1 OF 1  WPIDS  COPYRIGHT 2004 THE THOMSON CORP on STN
AN   2002-667977 [72]   WPIDS
DNC  C2002-187773
TI   Use of proline-containing tripeptide for treating neurodegeneration,
     useful particularly in early stages of Alzheimer's disease.
DC   B02 B03
IN   GONELLA, J; GRUMEL, J; RAPIN, J; WITZMANN, H K
PA   (TELL-N) TELL-PHARM AG; (NEUR-N) NEUROTELL AG
CYC  101
PI   DE 10105039     A1 20020808 (200272)*      10    A61K038-06
     WO 2002062830   A1 20020815 (200272)  EN         C07K005-08
        RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
            NL OA PT SD SE SL SZ TR TZ UG ZM ZW
         W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
            DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
            KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
            RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM
            ZW
     EP 1358204      A1 20031105 (200377)  EN         C07K005-08
         R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
            RO SE SI TR
     AU 2002247685   A1 20020819 (200427)            C07K005-08
ADT  DE 10105039 A1 DE 2001-10105039 20010205; WO 2002062830 A1 WO 2002-EP1181
     20020205; EP 1358204 A1 EP 2002-716727 20020205, WO 2002-EP1181 20020205;
     AU 2002247685 A1 AU 2002-247685 20020205
FDT  EP 1358204 A1 Based on WO 2002062830; AU 2002247685 A1 Based on WO
     2002062830
PRAI DE 2001-10105039     20010205
IC   ICM  A61K038-06; C07K005-08
     ICS  A61P025-28


=> fil reg
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      11.98     822.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)            SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -42.00

FILE 'REGISTRY' ENTERED AT 10:43:58 ON 28 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 SEP 2004  HIGHEST RN 752974-11-1
DICTIONARY FILE UPDATES:  27 SEP 2004  HIGHEST RN 752974-11-1


Searched by: Mary Hale 571-272-2507 REM 1D86
```

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> del his y

=>

Searched by: Mary Hale 571-272-2507 REM 1D86